For Oman to successfully attract international medical tourists, its hospitals must guarantee uninterrupted access to cutting-edge medical devices, advanced therapeutics, and high quality pharmaceuticals. This requires a shift from import dependency to In-Country Value (ICV). With the Omani pharmaceutical market projected to exceed $1.24 billion by 2031, this theme positions local manufacturing not just as an economic diversifier, but as the critical supply chain backbone of health tourism.

This panel brings together the financial engines, the academic researchers, the pioneering biopharma manufacturers, and the private hospital buyers. The discussion will dissect how sovereign capital is financing health-tech joint ventures, how universities are bridging the gap between clinical trials and the factory floor, and ultimately, how private hospital networks integrate these localized technologies to offer premium, uninterrupted, and cost-effective care to international patients.